871 related articles for article (PubMed ID: 22093091)
21. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
22. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
23. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
[TBL] [Abstract][Full Text] [Related]
24. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy.
Bittner N; Merrick GS; Butler WM; Bennett A; Galbreath RW
J Urol; 2013 Aug; 190(2):509-14. PubMed ID: 23416641
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
[TBL] [Abstract][Full Text] [Related]
26. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy.
Numao N; Kawakami S; Yokoyama M; Yonese J; Arisawa C; Ishikawa Y; Ando M; Fukui I; Kihara K
Eur Urol; 2007 Dec; 52(6):1663-8. PubMed ID: 17240041
[TBL] [Abstract][Full Text] [Related]
27. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.
Müntener M; Kunz U; Eichler K; Puhan M; Schmid DM; Sulser T; Strebel RT
Urol Int; 2010; 84(2):141-6. PubMed ID: 20215816
[TBL] [Abstract][Full Text] [Related]
28. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
29. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population.
Steiner H; Moser P; Hager M; Berger AP; Klocker H; Spranger R; Rogatsch H; Bartsch G; Horninger W
Prostate; 2004 Feb; 58(3):277-82. PubMed ID: 14743467
[TBL] [Abstract][Full Text] [Related]
31. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
32. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
[TBL] [Abstract][Full Text] [Related]
33. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy.
Hossack T; Patel MI; Huo A; Brenner P; Yuen C; Spernat D; Mathews J; Haynes AM; Sutherland R; del Prado W; Stricker P
J Urol; 2012 Sep; 188(3):781-5. PubMed ID: 22819419
[TBL] [Abstract][Full Text] [Related]
34. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
35. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment?
Brausi M; Castagnetti G; Dotti A; De Luca G; Olmi R; Cesinaro AM
J Urol; 2004 Sep; 172(3):906-8; discussion 908-9. PubMed ID: 15310995
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
37. Complications of transrectal versus transperineal prostate biopsy.
Miller J; Perumalla C; Heap G
ANZ J Surg; 2005; 75(1-2):48-50. PubMed ID: 15740517
[TBL] [Abstract][Full Text] [Related]
38. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
[TBL] [Abstract][Full Text] [Related]
39. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.
Kvåle R; Møller B; Wahlqvist R; Fosså SD; Berner A; Busch C; Kyrdalen AE; Svindland A; Viset T; Halvorsen OJ
BJU Int; 2009 Jun; 103(12):1647-54. PubMed ID: 19154461
[TBL] [Abstract][Full Text] [Related]
40. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
